Introduction {#s1}
============

Stargardt\'s disease (STGD) is a common hereditary retinal dystrophy leading to irreversible bilateral visual acuity loss.[@i2164-2591-8-6-26-b01] It is characterized by a diffusely compromised retinal pigmented epithelium (RPE)/photoreceptor complex, with heterogeneous manifestations detectable both at the macular level and in the middle and extreme periphery.[@i2164-2591-8-6-26-b02],[@i2164-2591-8-6-26-b03] Recently developed noninvasive imaging technology, principally optical coherence tomography (OCT) and OCT angiography (OCTA), has led to a better understanding of the underlying pathologic mechanisms governing the onset and progression of the atrophic process, revealing a connection with the damage to the retinal and choroidal vascular network.[@i2164-2591-8-6-26-b04][@i2164-2591-8-6-26-b05]--[@i2164-2591-8-6-26-b06]

The aim of the present study was to analyze quantitative OCTA parameters in order to identify clinically relevant cutoff values.

Materials and Methods {#s2}
=====================

The study was designed as an observational cross-sectional analysis. Consecutive patients affected by STGD were recruited in the Heredodystrophies Unit of the Department of Ophthalmology of San Raffaele Hospital in Milan. Each patient provided signed informed consent before the examination, in accordance with the Declaration of Helsinki. The study was approved by the Ethical Committee of the Vita-Salute San Raffaele University of Milan. The inclusion criteria were as follows: *ABCA4* genetically confirmed diagnosis of STGD and age from 18 to 70 years. The following exclusion criteria were applied: refractive errors greater than ±3 diopters (D), increased media opacity, glaucoma and other types of retinal and/or optic nerve diseases (e.g., diabetic retinopathy), any ophthalmic surgery in the last 6 months, any systemic conditions potentially affecting the results of the study.

All the patients underwent a complete ophthalmologic examination, including best-corrected visual acuity (BCVA) using standard Early Treatment Diabetic Retinopathy Study charts, slit-lamp evaluation of anterior and posterior segments, intraocular pressure measurement with a Goldmann applanation tonometer, color fundus photography, and fundus autofluorescence. In addition, structural OCT and OCTA images were acquired by means of Heidelberg Spectralis HRA+OCT (Heidelberg Engineering, Heidelberg, Germany) and SS-OCT DRI Topcon Triton (Topcon Corporation, Tokyo, Japan), respectively. The OCT acquisition protocol included high-resolution radial and raster scans, while OCTA analysis included 3 × 3- and 4.5 × 4.5-mm scans, centered at the level of both the macula and the optic nerve head. Eye tracking was used to assess possible fixation loss. Only high-quality images, evaluated by means of Topcon index quality (\>70), were considered.

We measured retinal layer thickness by means of a high-resolution horizontal structural enhanced-depth imaging (EDI)-OCT scan,[@i2164-2591-8-6-26-b07] including total retinal thickness, central macular thickness (CMT), retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL) and ellipsoid zone--retinal pigment epithelium layer (EZ-RPE). Choroidal thickness was also measured. For each measure, four samplings were obtained on the left and four on the right of the foveal, the mean value being used in the analysis. Moreover, hyperreflective foci (HF) (defined as discrete, punctiform, hyperreflective lesions) were measured in the same structural OCT scan, within both the retina and the choroid, but using inverted colors to improve the imaging. HF were analyzed in a region selected on a horizontal structural OCT, including 750 μm on the right and left sides of a vertical line passing through the fovea. Fundus autofluorescence (FAF) images were also used to assess the presence of foveal sparing, defined as the absence of autofluorescence surrounding the fovea by least 180°, not including the fovea.[@i2164-2591-8-6-26-b08] A control group of healthy age- and sex-matched subjects underwent the same ophthalmologic assessment.

OCTA images were analyzed by the Topcon full-spectrum, amplitude-decorrelation, angiography algorithm. Each patient contributed with a single eye, which was randomly selected.

The superficial capillary plexuses (SCP), deep capillary plexuses (DCP), and choriocapillaris (CC) were automatically segmented both in the macula and in the optic nerve head; additionally, the radial peripapillary capillary (RPC) plexus was automatically segmented at the level of the optic nerve. For convenience, macular parameters will henceforth be referred to using the prefix "m," with the prefix "n" applying to the optic nerve head (e.g., mSCP and nSCP for macular and nerve superficial capillary plexuses, respectively).

Each reconstruction was carefully inspected by an expert ophthalmologist (MBP). All reconstructions were exported in .tiff format and loaded in ImageJ software (Bethesda, MD). In-house scripts were built in order to calculate the following parameters: vessel density (VD), vessel tortuosity (VT), vessel dispersion (Vdisp), and vessel rarefaction (VR), with the same approach already adopted.[@i2164-2591-8-6-26-b09]

The statistical analysis of the quantitative parameters considered, comparing with control values, was performed using the one-way ANOVA test, with Bonferroni correction for multiple comparisons (SPSS, Chicago, IL). Moreover, statistically significant correlations between all considered parameters were assessed by means of Kendall\'s tau correlation coefficient measurement. We also performed a receiver operating curve (ROC) analysis in order to extract a parameter that could distinguish STGD subgroups differing significantly in terms of BCVA. The statistical significance was set at *P* \< 0.05.

Results {#s3}
=======

Overall, 54 eyes of 54 STGD patients (18 males) were included in the analysis, and all data were compared with 54 eyes of 54 healthy age- and sex-matched controls. All clinical and imaging findings are extensively reported in [Table 1](#i2164-2591-8-6-26-t01){ref-type="table"}. Duration of STGD, as assessed on the patients\' report, was 12.8 ± 10.8 years. The standout finding was STGD patients showed statistically significant worse BCVA, structural OCT parameters, and OCTA parameters. Moreover, we detected significantly higher HF numbers, both within the retina and the choroid in our patients\' cohort, with respect to the control group. Partial or complete foveal sparing was detected in 23 of 54 patients (43%). Correlation analyses revealed several statistically significant correlations ([Table 2](#i2164-2591-8-6-26-t02){ref-type="table"}). In more detail, BCVA was influenced by the integrity both of the retinal layers and vascular network. The presence of HF was found to correlate with worse BCVA. Furthermore, both retinal layer thickness and HF number significantly correlated with OCTA parameters. In particular, high VD and VT values were associated with better structural features and lower HF number, whereas high VDisp and VR values were related to worse retinal status and higher HF number. It is worth noting the higher significant correlations with both VD and VT, compared with VDisp and VR parameters. Statistically significant correlations were found when considering macular OCTA parameters alone, optic nerve head parameters showing unremarkable effects ([Figs. 1](#i2164-2591-8-6-26-f01){ref-type="fig"} and [2](#i2164-2591-8-6-26-f02){ref-type="fig"}). Interestingly, retinal layer thickness showed a stronger correlation with VT values than with VD. In addition, as expected, OCTA parameters showed statistically significant correlations between them (*P* \< 0.01). No significant age or duration effect were detected. ROC analysis established a cutoff value based on the VT mean, to separate two subgroups with different BCVA, with both sensitivity and specificity of 0.9. A VT cutoff of 5 created two categories, a functionally and anatomically better STGD group (STGD1) and a worse group (STGD2) ([Table 3](#i2164-2591-8-6-26-t05){ref-type="table"}). Foveal sparing was present in 15 of 35 patients of STGD1 (43%) and in 8 of 19 patients of STGD2 (42%) (*P* \> 0.05), showing no effects on the analyses.

###### 

Clinical and Imaging Findings

  Parameter             STGD Patients   Controls   *P* Value           
  --------------------- --------------- ---------- ----------- ------- -------------
  Age                   43.52           16.39      45.37       17.93   *P* \> 0.05
  BCVA, logMAR          0.68            0.44       0.00        0.00    *P* \< 0.01
  RNFL                  97.86           9.45       106.53      9.63    
  EZ-RPE                43.87           21.37      73.01       5.55    
  ONL                   26.19           14.10      92.34       7.25    
  OPL                   20.12           9.90       41.51       5.98    
  INL                   33.15           7.71       46.17       6.46    
  IPL                   34.84           8.85       48.21       7.12    
  GCL                   44.21           11.21      62.49       7.48    
  CMT                   103.05          59.03      241.03      11.16   
  Retinal thickness     224.23          54.24      400.66      19.06   
  Choroidal thickness   257.01          94.71      322.53      44.37   
  HF_retina             7.76            7.35       0.00        0.00    
  HF_choroid            18.26           17.86      0.00        0.00    
  VD mSCP               0.40            0.02       0.41        0.01    
  VD mDCP               0.26            0.06       0.43        0.01    
  VD mCC                0.32            0.16       0.50        0.01    
  VDisp mSCP            24.62           8.72       10.72       4.15    
  VDisp mDCP            27.51           8.75       11.45       3.48    
  VT mSCP               5.31            0.15       7.20        0.31    
  VT mDCP               4.80            0.50       7.84        0.34    
  VR mSCP               0.44            0.03       0.39        0.01    
  VR mDCP               0.47            0.03       0.41        0.01    
  VD RPC                0.42            0.02       0.44        0.01    
  VD nSCP               0.41            0.03       0.43        0.01    
  VD nDCP               0.30            0.02       0.40        0.02    
  VD nCC                0.51            0.03       0.54        0.03    
  VDisp RPC             24.78           8.82       10.61       3.70    
  VDisp nSCP            25.80           11.56      10.35       2.88    
  VDisp nDCP            27.43           9.72       10.37       3.36    
  VT RPC                5.64            0.51       7.73        0.30    
  VT nSCP               4.45            0.26       8.42        0.33    
  VT nDCP               5.20            0.27       7.06        0.25    
  VR RPC                0.47            0.02       0.45        0.01    
  VR nSCP               0.49            0.02       0.44        0.01    
  VR nDCP               0.43            0.02       0.40        0.01    

###### 

Correlation Analysis

  Parameter                     RNFL          EZ−RPE        ONL           INL           IPL           GCL           CMT          Full_Retina
  ----------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------ -------------
  BCVA logMAR                                                                                                                    
   Kendall\'s tau coefficient   −0.248        −0.939        −0.938        −0.939        −0.941        −0.94         −0.938       −0.938
   *P* value                    \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01       \<0.01
                                ONL           INL           IPL           GCL           CMT           Full_retina   HF_retina    HF_choroid
  EZ-RPE                                                                                                                         
   Kendall\'s tau coefficient   0.996         0.995         0.993         0.994         0.998         0.998         −0.548       −0.658
   *P* value                    \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01       \<0.01
                                INL           IPL           GCL           CMT           Full_retina   HF_retina     HF_choroid   VD mCC
  ONL                                                                                                                            
   Kendall\'s tau coefficient   0.994         0.994         0.993         0.996         0.997         −0.545        −0.66        0.963
   *P* value                    \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01       \<0.01
                                IPL           GCL           CMT           Full_retina   HF_retina     HF_choroid    VD mCC       VT mSCP
  INL                                                                                                                            
   Kendall\'s tau coefficient   0.992         0.993         0.995         0.996         −0.551        −0.661        0.962        0.99
   *P* value                    \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01       \<0.01
                                GCL           CMT           Full_retina   HF_retina     HF_choroid    VD mCC        VT mSCP      VT mDCP
  IPL                                                                                                                            
   Kendall\'s tau coefficient   0.991         0.993         0.994         −0.545        −0.663        0.959         0.987        0.992
   *P* value                    \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01       \<0.01
                                CMT           Full_retina   HF_retina     HF_choroid    VD mCC        VT mSCP       VT mDCP      VT RPC
  GCL                                                                                                                            
   Kendall\'s tau coefficient   0.994         0.994         −0.548        −0.662        0.961         0.989         0.993        0.993
   *P* value                    \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01       \<0.01
                                Full_retina   HF_retina     HF_choroid    VD mCC        VT mSCP       VT mDCP       VT RPC       VR mSCP
  CMT                                                                                                                            
   Kendall\'s tau coefficient   0.998         −0.546        −0.658        0.964         0.991         0.996         0.995        −0.951
   *P* value                    \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01       \<0.01
                                HF_retina     HF_choroid    VD mCC        VT mSCP       VT mDCP       VT RPC        VR mSCP      VR mDCP
  Full_retina                                                                                                                    
   Kendall\'s tau coefficient   −0.547        −0.658        0.965         0.991         0.998         0.997         −0.951       −0.961
   *P* value                    \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01       \<0.01
                                HF_choroid    VD mCC        VT mSCP       VT mDCP       VT RPC        VR mSCP       VR mDCP      VR RPC
  HF_retina                                                                                                                      
   Kendall\'s tau coefficient   0.665         −0.516        −0.554        −0.547        −0.547        0.535         0.549        0.526
   *P* value                    \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01       \<0.01
                                VD mCC        VT mSCP       VT mDCP       VT RPC        VR mSCP       VR mDCP       VR RPC       
  HF_choroid                                                                                                                     
   Kendall\'s tau coefficient   −0.625        −0.657        −0.657        −0.657        0.628         0.663         0.679        
   *P* value                    \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01        \<0.01       

###### 

Extended

  Parameter                     HF_retina   HF_choroid   VD mCC    VD nCC    VT mSCP   VT mDCP   VT RPC    VR mSCP
  ----------------------------- ----------- ------------ --------- --------- --------- --------- --------- ---------
  BCVA logMAR                                                                                              
   Kendall\'s tau coefficient   0.56        0.697        −0.903    0.366     −0.943    −0.939    −0.938    0.925
   *P* value                    \<0.01      \<0.01       \<0.01    \<0.01    \<0.01    \<0.01    \<0.01    \<0.01
                                VD mCC      VT mSCP      VT mDCP   VT RPC    VR mSCP   VR mDCP   VR RPC    VT Mean
  EZ-RPE                                                                                                   
   Kendall\'s tau coefficient   0.964       0.992        0.997     0.995     −0.952    −0.962    −0.913    0.735
   *P* value                    \<0.01      \<0.01       \<0.01    \<0.01    \<0.01    \<0.01    \<0.01    \<0.01
                                VT mSCP     VT mDCP      VT RPC    VR mSCP   VR mDCP   VR RPC    VT Mean   VR Mean
  ONL                                                                                                      
   Kendall\'s tau coefficient   0.991       0.997        0.997     −0.951    −0.963    −0.913    0.735     −0.725
   *P* value                    \<0.01      \<0.01       \<0.01    \<0.01    \<0.01    \<0.01    \<0.01    \<0.01
                                VT mDCP     VT RPC       VR mSCP   VR mDCP   VR RPC    VT Mean   VR Mean   
  INL                                                                                                      
   Kendall\'s tau coefficient   0.995       0.993        −0.952    −0.961    −0.914    0.736     −0.726    
   *P* value                    \<0.01      \<0.01       \<0.01    \<0.01    \<0.01    \<0.01    \<0.01    
                                VT RPC      VR mSCP      VR mDCP   VR RPC    VT Mean   VR Mean             
  IPL                                                                                                      
   Kendall\'s tau coefficient   0.993       −0.953       −0.961    −0.918    0.738     −0.726              
   *P* value                    \<0.01      \<0.01       \<0.01    \<0.01    \<0.01    \<0.01              
                                VR mSCP     VR mDCP      VR RPC    VT Mean   VR Mean                       
  GCL                                                                                                      
   Kendall\'s tau coefficient   −0.952      −0.962       −0.917    0.731     −0.729                        
   *P* value                    \<0.01      \<0.01       \<0.01    \<0.01    \<0.01                        
                                VR mDCP     VR RPC       VT Mean   VR Mean                                 
  CMT                                                                                                      
   Kendall\'s tau coefficient   −0.962      −0.914       0.735     −0.724                                  
   *P* value                    \<0.01      \<0.01       \<0.01    \<0.01                                  
                                VR RPC      VD Mean      VT Mean   VR Mean                                 
  Full_retina                                                                                              
   Kendall\'s tau coefficient   −0.913      0.373        0.738     −0.724                                  
   *P* value                    \<0.01      \<0.01       \<0.01    \<0.01                                  
                                                                                                           
  HF_retina                                                                                                
   Kendall\'s tau coefficient                                                                              
   *P* value                                                                                               
                                                                                                           
  HF_choroid                                                                                               
   Kendall\'s tau coefficient                                                                              
   *P* value                                                                                               

###### 

Extended

  Parameter                     VR mDCP
  ----------------------------- ---------
  BCVA logMAR                   
   Kendall\'s tau coefficient   0.939
   *P* value                    \<0.01
                                VR Mean
  EZ-RPE                        
   Kendall\'s tau coefficient   −0.723
   *P* value                    \<0.01
                                
  ONL                           
   Kendall\'s tau coefficient   
   *P* value                    
                                
  INL                           
   Kendall\'s tau coefficient   
   *P* value                    
                                
  IPL                           
   Kendall\'s tau coefficient   
   *P* value                    
                                
  GCL                           
   Kendall\'s tau coefficient   
   *P* value                    
                                
  CMT                           
   Kendall\'s tau coefficient   
   *P* value                    
                                
  Full_retina                   
   Kendall\'s tau coefficient   
   *P* value                    
                                
  HF_retina                     
   Kendall\'s tau coefficient   
   *P* value                    
                                
  HF_choroid                    
   Kendall\'s tau coefficient   
   *P* value                    

![Macular OCTA in STGD. SCP (A) and DCP (B) appear evidently rarefied in STGD. Furthermore, CC (C) results almost absent, with clear exposure of choroidal vessels. SCP, DCP, and CC plexa of a healthy control are shown in (D--F), respectively.](i2164-2591-8-6-26-f01){#i2164-2591-8-6-26-f01}

![Optic nerve head OCTA in STGD. If comparing a STGD patient with a healthy control, RPC (A), SCP (B), and DCP (C) appear evidently rarefied in STGD. Moreover, also CC plexus shows signs of perfusion lacks (D). RPC, SCP, DCP, and CC plexa of a healthy control are shown in (E--H), respectively.](i2164-2591-8-6-26-f02){#i2164-2591-8-6-26-f02}

###### 

OCTA VT Cutoff Analysis (VT = 5)

  Parameter                Mean ± SD       Comparison           *P* Values
  ------------------------ --------------- -------------------- ------------
  Age                                                           
   STGD1                   44 ± 15         STGD1 vs. STGD2      \>0.05
   STGD2                   44 ± 19         STGD1 vs. Controls   \>0.05
   Controls                45 ± 17         STGD2 vs. Controls   \>0.05
  BCVA, logMAR                                                  
   STGD1                   0.42 ± 0.28     STGD1 vs. STGD2      \<0.01
   STGD2                   1.09 ± 0.36     STGD1 vs. Controls   \<0.01
   Controls                0.0 ± 0.0       STGD2 vs. Controls   \<0.01
  RNFL                                                          
   STGD1                   98 ± 9          STGD1 vs. STGD2      \>0.05
   STGD2                   98 ± 10         STGD1 vs. controls   \<0.01
   Controls                107 ± 10        STGD2 vs. Controls   \<0.01
  CMT                                                           
   STGD1                   129 ± 58        STGD1 vs. STGD2      \<0.01
   STGD2                   65 ± 48         STGD1 vs. Controls   \<0.01
   Controls                240 ± 11        STGD2 vs. Controls   \<0.01
  Full retinal thickness                                        
   STGD1                   248 ± 52        STGD1 vs. STGD2      \<0.01
   STGD2                   189 ± 42        STGD1 vs. Controls   \<0.01
   Controls                403 ± 16        STGD2 vs. Controls   \<0.01
  CT                                                            
   STGD1                   268 ± 92        STGD1 vs. STGD2      \>0.05
   STGD2                   242 ± 99        STGD1 vs. controls   \<0.05
   Controls                322 ± 45        STGD2 vs. controls   \<0.01
  EZ-RPE                                                        
   STGD1                   55 ± 19         STGD1 vs. STGD2      \<0.01
   STGD2                   26 ± 13         STGD1 vs. controls   \<0.01
   Controls                73 ± 6          STGD2 vs. controls   \<0.01
  ONL                                                           
   STGD1                   33 ± 12         STGD1 vs. STGD2      \<0.01
   STGD2                   17 ± 15         STGD1 vs. controls   \<0.01
   Controls                93 ± 7          STGD2 vs. controls   \<0.01
  OPL                                                           
   STGD1                   21 ± 12         STGD1 vs. STGD2      \<0.01
   STGD2                   19 ± 7          STGD1 vs. controls   \<0.01
   Controls                42 ± 6          STGD2 vs. controls   \<0.01
  INL                                                           
   STGD1                   37 ± 7          STGD1 vs. STGD2      \<0.01
   STGD2                   27 ± 4          STGD1 vs. controls   \<0.01
   Controls                47 ± 6          STGD2 vs. controls   \<0.01
  IPL                                                           
   STGD1                   39 ± 8          STGD1 vs. STGD2      \<0.01
   STGD2                   27 ± 4          STGD1 vs. controls   \<0.01
   Controls                49 ± 7          STGD2 vs. controls   \<0.01
  GCL                                                           
   STGD1                   50 ± 8          STGD1 vs. STGD2      \<0.01
   STGD2                   34 ± 7          STGD1 vs. controls   \<0.01
   Controls                63 ± 7          STGD2 vs. controls   \<0.01
  HF_retina                                                     
   STGD1                   7 ± 7           STGD1 vs. STGD2      \<0.05
   STGD2                   10 ± 7          STGD1 vs. controls   \<0.01
   Controls                0 ± 0           STGD2 vs. controls   \<0.01
  HF_choroid                                                    
   STGD1                   11 ± 11         STGD1 vs. STGD2      \<0.01
   STGD2                   30 ± 20         STGD1 vs. controls   \<0.01
   Controls                0 ± 0           STGD2 vs. controls   \<0.01
  VD mSCP                                                       
   STGD1                   0.40 ± 0.02     STGD1 vs. STGD2      \>0.05
   STGD2                   0.40 ± 0.02     STGD1 vs. controls   \<0.01
   Controls                0.41 ± 0.01     STGD2 vs. controls   \<0.01
  VD mDCP                                                       
   STGD1                   0.26 ± 0.06     STGD1 vs. STGD2      \>0.05
   STGD2                   0.28 ± 0.07     STGD1 vs. controls   \<0.01
   Controls                0.43 ± 0.01     STGD2 vs. controls   \<0.01
  VD mCC                                                        
   STGD1                   0.42 ± 0.03     STGD1 vs. STGD2      \<0.01
   STGD2                   0.17 ± 0.17     STGD1 vs. controls   \<0.01
   Controls                0.50 ± 0.01     STGD2 vs. controls   \<0.01
  VD RPC                                                        
   STGD1                   0.42 ± 0.02     STGD1 vs. STGD2      \>0.05
   STGD2                   0.42 ± 0.02     STGD1 vs. controls   \<0.01
   Controls                0.44 ± 0.01     STGD2 vs. controls   \<0.01
  VD nSCP                                                       
   STGD1                   0.41 ± 0.03     STGD1 vs. STGD2      \>0.05
   STGD2                   0.40 ± 0.04     STGD1 vs. controls   \>0.05
   Controls                0.43 ± 0.01     STGD2 vs. controls   \<0.05
  VD nDCP                                                       
   STGD1                   0.30 ± 0.02     STGD1 vs. STGD2      \>0.05
   STGD2                   0.30 ± 0.03     STGD1 vs. controls   \<0.01
   Controls                0.40 ± 0.02     STGD2 vs. controls   \<0.01
  VD nCC                                                        
   STGD1                   0.50 ± 0.02     STGD1 vs. STGD2      \<0.01
   STGD2                   0.52 ± 0.04     STGD1 vs. controls   \<0.01
   Controls                0.54 ± 0.03     STGD2 vs. controls   \<0.01
  VD mean                                                       
   STGD1                   0.39 ± 0.01     STGD1 vs. STGD2      \<0.01
   STGD2                   0.36 ± 0.03     STGD1 vs. controls   \<0.01
   Controls                0.45 ± 0.01     STGD2 vs. controls   \<0.01
  Vdisp mSCP                                                    
   STGD1                   23.86 ± 6.43    STGD1 vs. STGD2      \>0.05
   STGD2                   25.54 ± 11.83   STGD1 vs. controls   \<0.01
   Controls                10.53 ± 4.08    STGD2 vs. controls   \<0.01
  Vdisp mDCP                                                    
   STGD1                   27.71 ± 9.61    STGD1 vs STGD2       \>0.05
   STGD2                   26.50 ± 7.54    STGD1 vs. controls   \<0.01
   Controls                11.36 ± 3.50    STGD2 vs. controls   \<0.01
  Vdisp RPC                                                     
   STGD1                   26.71 ± 9.46    STGD1 vs. STGD2      \<0.01
   STGD2                   20.62 ± 6.74    STGD1 vs. controls   \<0.01
   Controls                10.67 ± 3.75    STGD2 vs. controls   \<0.01
  Vdisp nSCP                                                    
   STGD1                   28.41 ± 12.61   STGD1 vs. STGD2      \<0.01
   STGD2                   20.40 ± 7.72    STGD1 vs. controls   \<0.01
   Controls                10.40 ± 2.92    STGD2 vs. controls   \<0.01
  Vdisp nDCP                                                    
   STGD1                   28.37 ± 9.49    STGD1 vs. STGD2      \>0.05
   STGD2                   24.75 ± 10.80   STGD1 vs. controls   \<0.01
   Controls                10.50 ± 3.34    STGD2 vs. controls   \<0.01
  VDisp mean                                                    
   STGD1                   27.01 ± 6.58    STGD1 vs. STGD2      \<0.05
   STGD2                   23.56 ± 5.61    STGD1 vs. controls   \<0.01
   Controls                10.69 ± 1.37    STGD2 vs. controls   \<0.01
  VT mSCP                                                       
   STGD1                   5.39 ± 0.11     STGD1 vs. STGD2      \>0.05
   STGD2                   5.27 ± 0.44     STGD1 vs. controls   \<0.01
   Controls                7.20 ± 0.31     STGD2 vs. controls   \<0.01
  VT mDCP                                                       
   STGD1                   5.08 ± 0.31     STGD1 vs. STGD2      \>0.05
   STGD2                   4.46 ± 0.84     STGD1 vs. controls   \<0.01
   Controls                7.85 ± 0.35     STGD2 vs. controls   \<0.01
  VT RPC                                                        
   STGD1                   5.93 ± 0.30     STGD1 vs. STGD2      \>0.05
   STGD2                   5.24 ± 0.66     STGD1 vs. controls   \<0.01
   Controls                7.73 ± 0.30     STGD2 vs. controls   \<0.01
  VT nSCP                                                       
   STGD1                   4.49 ± 0.30     STGD1 vs. STGD2      \>0.05
   STGD2                   4.56 ± 0.87     STGD1 vs. controls   \<0.01
   Controls                8.43 ± 0.33     STGD2 vs. controls   \<0.01
  VT nDCP                                                       
   STGD1                   5.24 ± 0.30     STGD1 vs. STGD2      \>0.05
   STGD2                   5.19 ± 0.42     STGD1 vs. controls   \<0.01
   Controls                7.07 ± 0.25     STGD2 vs. controls   \<0.01
  VT mean                                                       
   STGD1                   5.23 ± 0.15     STGD1 vs. STGD2      \<0.01
   STGD2                   4.94 ± 0.61     STGD1 vs. controls   \<0.01
   Controls                7.66 ± 0.23     STGD2 vs. controls   \<0.01
  VR mSCP                                                       
   STGD1                   0.43 ± 0.02     STGD1 vs. STGD2      \<0.01
   STGD2                   0.47 ± 0.03     STGD1 vs. controls   \<0.01
   Controls                0.39 ± 0.01     STGD2 vs. controls   \<0.01
  VR mDCP                                                       
   STGD1                   0.45 ± 0.02     STGD1 vs. STGD2      \<0.01
   STGD2                   0.50 ± 0.03     STGD1 vs. controls   \<0.01
   Controls                0.41 ± 0.01     STGD2 vs. controls   \<0.01
  VR RPC                                                        
   STGD1                   0.46 ± 0.01     STGD1 vs. STGD2      \<0.01
   STGD2                   0.49 ± 0.01     STGD1 vs. controls   \<0.01
   Controls                0.44 ± 0.01     STGD2 vs. controls   \<0.01
  VR nSCP                                                       
   STGD1                   0.49 ± 0.02     STGD1 vs. STGD2      \<0.01
   STGD2                   0.48 ± 0.02     STGD1 vs. controls   \<0.01
   Controls                0.44 ± 0.01     STGD2 vs. controls   \<0.01
  VR nDCP                                                       
   STGD1                   0.43 ± 0.02     STGD1 vs. STGD2      \<0.01
   STGD2                   0.42 ± 0.02     STGD1 vs. controls   \<0.01
   Controls                0.40 ± 0.01     STGD2 vs. controls   \<0.01
  VR mean                                                       
   STGD1                   0.45 ± 0.01     STGD1 vs. STGD2      \<0.01
   STGD2                   0.47 ± 0.02     STGD1 vs. controls   \<0.01
   Controls                0.42 ± 0.01     STGD2 vs. controls   \<0.01

Discussion {#s4}
==========

STGD is a complex disease primarily associated with RPE/photoreceptor dysfunction and is accompanied by a compromised vascular network, which can be noninvasively analyzed by OCTA.[@i2164-2591-8-6-26-b06] In particular, macular CC alterations represent a key element contributing to outer retinal atrophy.[@i2164-2591-8-6-26-b04]

The aim of the present study was to analyze both retinal layer and vascular network changes in STGD. A significant thinning of inner and outer retinal layers, together with the presence of relevant alterations of the retinal vascular network were found, providing further confirmation of the CC macular damage. Although significant dysfunction of the optic nerve head plexa was detected, these changes may be interpreted as a consequence of modifications to the retina. Quantitative OCTA parameters, including VT, VDisp, and VR, enabled the involvement of the retinal vascular network in STGD to be described in greater detail. In particular, retinal plexa appeared rarer and more disorganized than in controls, VT reduction representing the consequence of reduced blood flow perfusion.[@i2164-2591-8-6-26-b09]

The dysfunction present throughout the retinal vascular network may be due to the primary RPE/photoreceptor damage. Indeed, the RPE is essential to the physiologic release of growth factors, including VEGF, which guarantee the trophism of retinal vessels and CC, along with the regulation of metabolic exchanges through the blood--retinal barrier (Le YZ, et al. *IOVS*. 2008;49:E−Abstract 857).[@i2164-2591-8-6-26-b10] With regard to inner retinal thinning, this finding might be explained as inner retinal cell damage caused by anterograde degeneration, taking into account the exclusive expression of the *ABCA4* gene in the RPE/photoreceptor complex.[@i2164-2591-8-6-26-b11] Alternatively, the loss of trophic stimuli from RPE cells, in addition to the retinal vascular network deficiency, may contribute to inner retinal degeneration and thinning. The results of the correlation analysis, especially the strong correlation revealed between retinal layer thickness and VT, further underline the influence of the impaired blood supply in the progression of the degenerative process occurring in STGD.

The higher number of retinal and choroidal HF in STGD patients has already been described[@i2164-2591-8-6-26-b12] and represents an imaging biomarker of the disease\'s activity, as reported in other conditions.[@i2164-2591-8-6-26-b13]

The most interesting findings of the present paper are the results of the cutoff analyses of OCTA parameters. A VT cutoff value of 5, obtained from the mean of the values of all retinal plexa, was able to identify two different STGD groups on the basis of the BCVA. These patients\' subgroups also differed in terms of retinal layer thickness and OCTA parameters, thus enabling us to divide our patients\' cohort into better and worse morphofunctional groups. Interestingly, STGD1 and STGD2 subgroups did not differ significantly in terms of foveal sparing, suggesting that other factors besides the atrophic changes of the fovea contribute to the BCVA loss. We hypothesize that the more extensively dysfunctional vascular network typical of STGD2 is responsible for an overall decrease in macular functionality. In other words, assuming the same degree of foveal involvement, a more trophic vascular network leads to a better retinal function. Although obtained from what is only a pilot study, our findings may have important clinical implications. In particular, patient evaluation in clinical practice might benefit from the information provided by this kind of analysis, enabling different clinical phenotypes to be identified. Furthermore, viewed in the context of clinical trials designed to test potential drugs, this approach might have a role in patient selection and in assessing clinical and anatomic outcomes.

Our study has undoubted limitations. Both OCT and OCTA analyses are known to be potentially affected by a number of artifacts,[@i2164-2591-8-6-26-b14],[@i2164-2591-8-6-26-b15] so we adopted all possible precautions to minimize their potential effect on data analysis. We are also aware that our imaging-based analysis might certainly benefit from histopathologic validation. Last, our cases were insufficient to draw definitive conclusions and it would therefore be advisable to carry out a longitudinal follow-up of patients in order to confirm our data.

In essence, our study reveals that extensive changes both in the retinal vascular network and in the retinal layers can be detected in STGD. A quantitative cutoff based on VT can separate two different morphofunctional phenotypes.

We believe a quantitative assessment might contribute to more accurate patients\' categorization in a future scenario that sees possible new drugs combining with the introduction of artificial intelligence--based techniques to identify and treat STGD. Further studies are warranted to provide further support to the present findings.
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